Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 3

5(83.3%)

Phase 1

1(16.7%)

6Total

Phase 3(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03428477Phase 3Active Not Recruiting

EPA for Metastasis Trial 2

Role: collaborator

NCT06637657Recruiting

Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD

Role: collaborator

NCT01047683Phase 3Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Role: lead

NCT01047501Phase 3Completed

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

Role: lead

NCT01492361Phase 3Completed

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

Role: lead

NCT03885661Phase 1Completed

Vascepa to Accelerate Lipoprotein Uptake and Elimination

Role: collaborator

NCT04460651Phase 3Completed

PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial

Role: collaborator

All 7 trials loaded